RNA-seq analysis of nintedanib effects on interstitial pneumonia in preoperative NSCLC patients

Key Points

• Nintedanib shows significant effects on interstitial pneumonia, indicating possible therapeutic benefits.
• Changes in biomarkers resulted from RNA-seq analysis, revealing crucial insights early in treatment.
• Observational analysis demonstrates the potential for targeting lung diseases using nintedanib in NSCLC.
• Findings underscore the need for further studies to validate nintedanib's efficacy on interstitial pneumonia.